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Abstract
Introduction: Chronic pain is a common problem for patients with Machado-Joseph disease. Most of the chronic
pain in Machado-Joseph disease has been reported to be of musculoskeletal origin, but now there seems to be
different chronic pain in patients with Machado-Joseph disease.
Case presentation: A 29-year-old man (Han Chinese, Hoklo) with Machado-Joseph disease experienced severe
chronic pain in both feet, cutaneous thermal change, thermal hypersensitivity, focal edema, and sweating and had
a history of bone fracture. These symptoms were compatible with a diagnosis of complex regional pain syndrome.
After common analgesics failed to relieve his pain, gabapentin was added and titrated to 2000 mg/day (500 mg
every six hours) in less than two weeks. This relieved 40% of his pain and led to significant clinical improvement.
Conclusions: The pathophysiology of complex regional pain syndrome includes peripheral and central
sensitizations, the latter of which might be associated with the neurodegeneration in Machado-Joseph disease. In
this report, we suggest that gabapentin could inhibit central sensitization as an adjunct for complex regional pain
syndrome in patients with Machado-Joseph disease.
Introduction
Machado-Joseph disease (MJD), also called spinocerebel-
lar ataxia type 3, is the most common subtype of spino-
cerebellar ataxias worldwide and is caused by a CAG
trinucleotide repeat expansion in the coding region of
the MJD1 gene. The main features of MJD are ataxia
and ophthalmoparesis and pyramidal, extrapyramidal,
and amyotrophic signs [1]. Chronic pain is one of the
most disabling symptoms of MJD. Nearly 80% of the
chronic pain in MJD has been reported to be of muscu-
loskeletal origin [2]. To the best of our knowledge, no
previous case report has mentioned complex regional
pain syndrome (CRPS) in patients with MJD. In the case
reported here, a patient with MJD experienced symp-
toms of CRPS, which were relieved by gabapentin.
Case presentation
A 29-year-old man (Han Chinese, Hoklo) with a diagno-
sis of MJD and CAG repeat numbers of 14 and 70 in
the MJD1 gene had been confined to a wheelchair for
three years. He had a history of left humeral bone
fracture as a result of an accidental fall one year earlier.
Three months prior to his stay in the hospital, he began
to have severe regional pain in his feet. His pain was
spontaneous, continuing, and excruciating in the areas
mentioned above. He described it as like “originating
deeply from the bone” and denied any burning or lanci-
nating sensation. Moderate hair loss, focal edema, cuta-
neous thermal change with hypersensitivity to cold
temperatures, and intermittent sweating in both feet
were observed. Yet there was no light-touch allodynia,
fever, chill, or local tenderness. He could hardly do any-
thing except moan in bed in the daytime and yell and
kick almost every night.
Plain film of both feet revealed normal alignment and
no bone lesions. A nerve conduction study and electro-
myography revealed merely mild sensorimotor poly-
neuropathy. Quantitative sensory testing (QST) was
conducted for his severely depressed mood. During his
stay in the hospital, we used the visual analogue scale
(VAS) (0 for no pain and 10 for maximal pain) to mea-
sure his pain intensity [3]. Initially, his pain was mini-
mally relieved, from 10 to 8 on the VAS, by common
analgesics, including acetaminophen, diclofenac, and tra-
madol. On day four, gabapentin was added at a daily
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With an increasing daily dosage of gabapentin from
1200 to 2000 mg (500 mg every six hours), his pain was
gradually resolved from 8 to 4 on the VAS (Figure 1) by
day 10. The abnormal cutaneous thermal change and
edema also disappeared. As his pain diminished signifi-
cantly, we observed a remarkable improvement in his
quality of life: he slept better, was more mobile, and had
more daily activity. Finally, he could move around again
by wheelchair.
Discussion
In this case, all of the clinical features of pain-such as
spontaneous continuing regional pain with cutaneous
thermal change, thermal hypersensitivity, focal edema,
moderate hair loss as trophic change, sweating, immobi-
lity, and history of bone fracture-implied CRPS [4].
CRPS is characterized by a continuing (spontaneous or
evoked) regional pain that is seemingly disproportionate
in time or degree to any known trauma or lesion. In the
latest proposed criteria for CRPS, regional pain is not
limited to a nerve territory or dermatome, which is
usually accompanied by a distal predominance of abnor-
mal sensory, motor, sudomotor, vasomotor, and trophic
changes [5]. Mechanical or thermal hypersensitivity is
the hallmark of nociceptive pain compatible with CRPS
[6,7].
In the pathophysiology of CRPS, peripheral nerve or
soft tissue injuries trigger the initial peripheral nocicep-
tive sensitization caused by prostanoids, kinins, and
cytokines. Afterwards, the calcium influx and activity-
dependent plasticity alter the pain transmission neurons,
which undergo central sensitization and lead to a major
physiological change of the autonomic, pain, and motor
systems [8]. Given the small-fiber distal axonopathy that
is possibly a cause of CRPS [9], QST should be managed
for the evaluation of small-fiber functions with cold and
heat pain thresholds [10].
To the best of our knowledge, no large clinical trials
in the pharmacologic treatment for CRPS have been
conducted. Most of the pharmacologic rationales for
CRPS (such as topical agents, anti-epileptic drugs, tri-
cyclic anti-depressants, and opioids) were applied by the
treatment of other neuropathic pain syndromes, which
are strongly related to gabapentin [11]. It has been
reported that gabapentin at daily doses of 900 to 2400
mg [12,13] could be considered to control CRPS, but
the effects seemed to be limited. We suppose that, since
the neurodegeneration in MJD is multi-systemic (invol-
ving the somatosensory cortex), gabapentin might play a
role in central neuromodulation via the alpha-2-delta
subunit of the voltage-gated calcium channels [14]. This
successful experience suggests that the adjunctive effect
of gabapentin is due to inhibition at the central
sensitization.
Conclusions
Our experience offers a new option to patients with
MJD and chronic pain. The exact mechanism remains
to be elucidated; however, gabapentin could be consid-
ered an adjunct for the treatment of CRPS in patients
with MJD.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompany-
ing images. A copy of the written consent is available
for review by the Editor-in-Chief of this journal.
Figure 1 Visual analogue scale (VAS) and daily dosage of gabapentin (GBP) in the hospital.O u rp a t i e n t ’s pain was gradually resolved
from 8 to 4 on the VAS by an increase in GBP from 1200 to 2000 mg. VAS and GBP values are presented on the left y-axis and right y-axis,
respectively.
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